FDA’s Overcaution Carries Deadly Consequences

December 10, 2018

When the FDA sets out to evaluate a potential new drug, the agency’s overcaution makes the exercise more expensive and potentially deadly from patients who might benefit. Mark Flatten of the Goldwater Institute comments.


Subscribe to Cato Daily Podcast:

Listen on Apple Podcasts Get it on Google Play Subscribe via RSS Listen on Spotify 

Recent Cato Daily Podcast